mp.weixin.qq.com·· 6 hours agoPickScore91
ESMO 2026 Breast Cancer ADC Rapid Orals Cover Neoadjuvant Therapy, Overall Survival and Resistance Sequencing
In brief
Liangyihui compiles seven rapid oral reports on breast cancer ADCs from ESMO 2026, covering neoadjuvant treatment in HER2-positive early breast cancer, overall survival in metastatic TNBC, sequential strategies after ADC resistance, and clinical data on ADCs with novel targets.
Why it matters
Compiles multiple ESMO 2026 breast cancer ADC oral reports spanning early neoadjuvant therapy, late-line survival benefit, resistance sequencing, and China-developed data.
Source: mp.weixin.qq.com · mp.weixin.qq.com